Syril Pettit, DrPH, MEM, is the Executive Director of the Health and Environmental Sciences Institute (HESI), an international nonprofit organization that builds public-private partnerships in application-driven science for improving human and environmental health. As HESI’s senior leader, she has guided the scientific and strategic direction for the organization’s more than 600 members and its programs for the last 20-plus years. She holds a Doctorate in Public Health from University of North Carolina’s Gillings School of Global Public Health and a Masters in Environmental Management from Duke University.
In this episode, Dr. Pettit and I talk about how advances in cancer treatment have increased survivorship, but also resulted in patients living long enough to experience the long-term side effects of both primary and adjuvant therapies. Often these impact survivors’ physical, emotional, and even financial and social well-being. Dr. Pettit and her team conduct and support research and innovation that bridge the interests and inputs of patients, life sciences firms, academic medicine, clinicians, and public health toward a future of survivorship that supports all aspects of patients’ health, well-being, and thriving.
Links related to Dr. Pettit’s podcast:
- Cancer journal article, Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study
- BMC Cardio-Oncology journal article, Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
- Toxicological Sciences journal article, ToxPoint: Health Disparities, COVID-19, and Owning Our Share
- Science Translational Medicine journal article, Enhancing quality of life as a goal for anticancer therapeutics
- The Health and Environmental Sciences Institute (HESI) website
- The HESI Thrive grant initiative for cross-disciplinary cancer research design to improve survivorship and quality of life
